Home > Insider Trading > Filing (0001567619-21-019297)

Filing Details

Accession Number:: 0001567619-21-019297
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-11-03 19:12:12
Reporting Period:: 2021-11-01

Accepted Time:: 2021-11-03 19:12:12
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1770787	10X Genomics Inc.	TXG	Laboratory Analytical Instruments (3826)	455614458

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1786391	J. Benjamin Hindson	C/O 10X Genomics, Inc. 6230 Stoneridge Mall Road Pleasanton CA 94588	See Remarks	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Class A Common Stock	Acquisiton	2021-11-01	10,232	$5.04	57,349	No	4	M	Direct
Class A Common Stock	Acquisiton	2021-11-01	31,434	$11.48	88,783	No	4	M	Direct
Class A Common Stock	Disposition	2021-11-01	1,100	$160.50	87,683	No	4	S	Direct
Class A Common Stock	Disposition	2021-11-01	1,500	$162.06	86,183	No	4	S	Direct
Class A Common Stock	Disposition	2021-11-01	11,829	$163.15	74,354	No	4	S	Direct
Class A Common Stock	Disposition	2021-11-01	24,125	$163.87	50,229	No	4	S	Direct
Class A Common Stock	Disposition	2021-11-01	3,112	$164.75	47,117	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Class A Common Stock	Stock Option (right to buy)	Disposition	2021-11-01	10,232	$0.00	10,232	$5.04
Class A Common Stock	Stock Option (right to buy)	Disposition	2021-11-01	31,434	$0.00	31,434	$11.48

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
50,884		2028-11-02	No	4	M	Direct
68,566		2029-05-10	No	4	M	Direct

Footnotes

The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
This transaction was executed in multiple trades at prices ranging from $160.00 to $160.95. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $161.45 to $162.43. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $162.48 to $163.475. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $163.48 to $164.47. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $164.50 to $165.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This option, originally for 175,000 shares, of which 124,116 shares have been exercised, vested as to 1/48th of the shares on October 1, 2018 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
This option, originally for 100,000 shares, of which 31,434 shares have been exercised, vested as to 1/48th of the shares on May 1, 2019 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.